Trends in Formulation eBook
Read the article:
Addressing Developmental Challenges of Gene Therapy Viral Vectors
Read the eBook:
Pharmaceutical Technology’s Trends in Formulation eBook
Significant improvements have been developed to tackle the challenges in viral vector manufacturing at each stage.
Sveta/Stock.adobe.com
Gene therapy has rapidly expanded conceptually and technically, now covering a wide array of tools and methods, including the advancement of viral vector delivery for gene therapies. Lentiviral vectors and adeno-associated virus (AAV) are two primary delivery mechanisms of gene therapies. While versatile and robust, there are some inherent weaknesses in the production of both AAV and lentivirus vectors, and, as a result, production is not well optimized. Over time, significant improvements have been developed to facilitate the manufacture of these viral vectors at each stage.
Read the article:
Addressing Developmental Challenges of Gene Therapy Viral Vectors
Read the eBook:
Pharmaceutical Technology’s Trends in Formulation eBook
Read this article in Pharmaceutical Technology’s October 2022 Trends in Formulation eBook.
Ger Brophy, is the executive vice-president of Biopharma Production, Arvind Srivastava is a technical fellow, Bioprocessing, and Greg Swan is business development manager for Cell & Gene Therapy; all are at Avantor.
Pharmaceutical Technology
eBook: Trends in Formulation, October 2022
October 2022
Pages: 36–40
When referring to this article, please cite it as G. Brophy, A. Srivastava, and G.Swan, “Addressing Developmental Challenges of Gene Therapy Viral Vectors," Pharmaceutical Technology Trends in Formulation eBook (October 2022).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
2 Commerce Drive
Cranbury, NJ 08512